After an update of its data from a clinical trial in the United States, Peru, and Chile, the Swedish-British laboratory has slightly revised down the effectiveness rate of its vaccine. Initially announced at 79%, the AstraZeneca vaccine would ultimately be 76% effective against symptomatic cases.
New data for the US regulator overseeing clinical trials
Administered in many countries including the European Union, the Swedish-British vaccine developed by AstraZeneca and the University of Oxford has not yet been approved in the United States. After the publication of the results of these clinical trials last Monday, the National Institute of Infectious Diseases and Allergies had announced its ” concern “As to the fact that the laboratory could” use obsolete information “As part of his tests thus judging to” an incomplete estimate of effectiveness Of the vaccine.
It is in this context that the American authorities have called for more data on the phase III trials carried out in the United States. The AstraZeneca laboratory thus committed this Tuesday, March 23, 2021 to provide recent data within 48 hours to the American regulator overseeing clinical trials.
76% effective against symptomatic forms and 100% against severe forms
While the first data had announced an effectiveness of 79% in preventing symptomatic cases, AstraZeneca has just revised the rate of effectiveness of its vaccine down by declaring that the latter is ultimately effective at 76% against symptomatic cases. In a press release issued this Thursday, March 25, 2021, the laboratory declared that the results of “ Primary analysis of Phase III trials of the vaccine in the United States confirmed that its efficacy was consistent With the data announced Monday. In addition, the laboratory also announced that the effectiveness of its vaccine is still 100% for severe cases of Covid-19.
While several countries have suspended its use in the face of the side effects observed in certain patients (in particular thrombosis), the AstraZeneca vaccine has been judged “ safe and efficient By the European Medicines Agency (EMA). Since then, its deployment has resumed in certain countries such as France. The United States could then follow suit and approve its use soon.
